Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan for idiopathic pulmonary fibrosis
ACTRN12609000458235Phase 2Active, not recruiting
- Sponsor
- Actelion
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Macitentan with Placebo (2 arms). Started May 2009; status: active, not recruiting.
02
Drugs
macitentan
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on ACTRN12609000458235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000458235.